Open access · CC-BY
via OpenAlex
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Yan Peng, Yuanyuan Wang, Cheng Zhou, Wuxuan Mei, Changchun Zeng
Frontiers in Oncology · 2022 · ▲ 810 citations
Abstract
Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and tumor complexity and heterogeneity necessitate customized medicine or targeted therapy. It is critical to identify potential cancer therapeutic targets. Aberrant activation of the PI3K/AKT/mTOR(definition) pathway has a significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR pathway alterations in cancer and various cancer hallmarks associated with the PI3K/AKT/mTOR pathway, such as cell proliferation, autophagy(definition), apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Importantly, this review provided recent advances in PI3K/AKT/mTOR inhibitor research. Overall, an in-depth understanding of the association between the PI3K/AKT/mTOR pathway and tumorigenesis and the development of therapies targeting the PI3K/AKT/mTOR pathway will help make clinical decisions.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fonc.2022.819128
- Canonical
- link ↗
- Fetched
- 2026-10-01 MST
Cite this
APA
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022). PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?. <em>Frontiers in Oncology</em>. https://doi.org/10.3389/fonc.2022.819128
Vancouver
Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?. Frontiers in Oncology. 2022. doi:10.3389/fonc.2022.819128.
BibTeX
@article{yan2022PIKAkt,
title = {PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?},
author = {Yan Peng and Yuanyuan Wang and Cheng Zhou and Wuxuan Mei and Changchun Zeng},
journal = {Frontiers in Oncology},
year = {2022},
doi = {10.3389/fonc.2022.819128},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
PLoS ONE 2015
Open access · CC-BY
Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics
International Journal of Molecular Sciences 2026
Open access · CC-BY
Regulatory Roles of Kaempferol on the PI3K/AKT/mTOR Signaling Pathway and Associated MicroRNAs in Different Cancer Types
Current Nutrition Reports 2023
Open access · OA
NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health
Science Advances 2023
Open access · CC-BY
What is really known about the effects of nicotinamide riboside supplementation in humans
Antioxidants 2022
Open access · CC-BY
Hormesis and Oxidative Distress: Pathophysiology of Reactive Oxygen Species and the Open Question of Antioxidant Modulation and Supplementation
Stem Cell Research & Therapy 2025
Open access · CC-BY